Mesalamine 800 mg delayed-release tablets have been launched, and FDA approval has been granted for lenalidomide, with plans for entry into the U.S. generic market in 2026.
Clearance was granted to bioMérieux's BIOFIRE FILMARRAY GI Panel Mid, a 1-hour molecular test that can detect 11 common gastroenteritis-causing pathogens from a single stool sample.
FDA approves aztreonam-avibactam, the first monobactam/β-lactamase inhibitor combination antibiotic, for treating complicated intra-abdominal infections in adults with limited treatment options.
Investigational drug in combination with weight-loss treatment preserves lean muscle mass in older patients with obesity, showing promising potential for reducing adiposity and achieving greater weight reduction.
Reuters
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Early trial results reveal promising outcomes as Novo Nordisk's next-generation obesity treatment, amycretin, shows potential for significant weight loss in participants.
“You are instilling fear into folks who may defer care, who may go without care, whose children may not get the vaccines they need, who may not be able to get treatment for an ear infection or surgery."
Upadacitinib, the first oral treatment for Crohn's disease, has been approved by the Food and Drug Administration. The approval came in part through a Mount Sinai-led clinical trial that showed it to be more efficacious than placebo.